Update (October 25): Merck has asked for approval of its molnupiravir pill from the European Medicines Agency, initiating a rolling review process as a step toward formal market authorization, the company announced today.
Update (October 11): Merck applied to the US Food and Drug Administration for emergency use of its antiviral pill today. The application specifies that the pill would be authorized only for high-risk adults such as the elderly or those who are immunocompromised, The New York Times reports.
Merck and Ridgeback Therapeutics announced today (October 1) that their oral drug molnupiravir cuts the risk of COVID-19–related hospitalization or death by 50 percent when administered within five days of the onset of COVID-19 symptoms. According to the companies’ news release, about 7 percent of the 385 trial participants who received the oral molnupiravir pill were hospitalized, and none died. The risk doubled among the 377 patients given a placebo, with about 14 percent hospitalized, and eight deaths. The data from the trials has not yet been peer-reviewed.
Merck will apply to the US Food and Drug Administration (FDA) for emergency use authorization for the drug “as soon as possible,” the announcement says.
According to STAT, the way the drug is administered sets it apart from other COVID-19 therapeutics. Monoclonal antibody treatments are currently limited to high-risk populations, such as the elderly or immune-compromised and are administered via injection or infusions. Another drug remdesivir must be given intravenously and is only available for hospitalized patients. Merck’s molnupiravir, in contrast, can be taken orally by outpatients. Virologist Angela Rasmussen of the University of Saskatchewan tells the Times that there could be “an objectively larger number of lives saved potentially with this drug” compared to other available COVID-19 treatments.
Experts also expect molnupiravir to be cheaper than other COVID-19 drugs, making it more accessible than, for example, monoclonal antibody treatments, which can cost several thousand dollars per patient according to the Times. If the drug is approved, Merck says it plans to use a tiered pricing framework for molnupiravir to account for different countries’ healthcare resources. Natalie Dean, an infectious disease researcher and biostatistics professor at Emory University, tells STAT, “The more accessible that can be, the more effective it can be.”
Merck had initially aimed to collect data on 1,500 participants in the trial, but halted early on the recommendation of an independent advisory board and the FDA due to its positive indicators of efficacy. The companies have not yet released information on what types of potential side effects the pill might have, but state in their news release that rates of adverse events in the treatment and placebo group were comparable. The Washington Post reports that animal experiments using molnupiravir indicate it is effective against variants such as Delta.
If it receives emergency use authorization, the pill could become the first clinically available oral antiviral treatment for COVID-19. Merck says it is seeking authorization from international regulators as well as the FDA. Meanwhile, competitors such as Atea Pharmaceuticals, Roche, and Pfizer are developing their own oral antiviral medications.